Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 16912956.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenz- or nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C-->T (odds ratio, 0.254; P=.021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P<.001).
Medical subject headings
- Anti-HIV Agents
- Chemical and Drug Induced Liver Injury
- Cytochrome P-450 Enzyme System
- Genes, MDR
- Nevirapine
- Oxazines
- Reverse Transcriptase Inhibitors